Comparison of the MicroScan system and the agar dilution assay for quinupristin/dalfopristin susceptibility of Enterococcus faecium

Annals of Clinical and Laboratory Science

Volumn 37, Issue 3, 2007, Pages 260-262

  Kim, Yang Ree ^a,d   Kim, Sang Il ^b,d   Hur, Ji Ahn ^c,d   Kim, Youn Jeong ^b,d   Wie, Seong Heon ^c,d   Park, Yeon Joon ^b,d   Kang, Moon Won ^b,d  

^a Uijeongbu St Mary's Hospital   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d The Catholic University of Korea   (South Korea)

Author keywords

Antimicrobial susceptibility testing; Enterococcus faecium; Quinupristin dalfopristin

Indexed keywords

DALFOPRISTIN PLUS QUINUPRISTIN; TEICOPLANIN; VANCOMYCIN; VIRGINIAMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; ENTEROCOCCUS FAECIUM; KOREA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; DRUG RESISTANCE, MICROBIAL; ENTEROCOCCUS FAECIUM; GRAM-POSITIVE BACTERIAL INFECTIONS; MICROBIAL SENSITIVITY TESTS; REPRODUCIBILITY OF RESULTS; TEICOPLANIN; VANCOMYCIN; VIRGINIAMYCIN;

ANIMALIA; ENTEROCOCCUS FAECIUM;

EID: 34548190980     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Oh WS, Ko KS, Song JH, Lee MY, Park S, Peck KR, Lee NY, Kim CK, Lee H, Kim SW, Chang HH, Kim YS, Jung SI, Son JS, Yeom JS, Ki HK, Woo GJ. High rate of resistance to Quinupristin-Dalfopristin in Enterococcus faecium clinical isolates from Korea. Antimicrob Agents Chemother 2005;49:5176-5178.
2. Hsueh PR, Chen WH, Teng LJ, Luh KT. Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents. Int J Antimicrob Agents 2005;26:43-49.
3. Luh KT, Husueh PR, Teng LJ, Pan HJ, Chen YC, Lu JJ, Wu JJ, Ho SW. Quinupristin-dalfopristin resistance among gram-positive bacteria in Taiwan. Antimicrob Agents Chemother 2000;44:374-380.
4. d'Azevedo PA, Dias CA, Goncalves AL, Rowe F, Teixeria LM. Evaluation of an automated system for the identification and microbial susceptibility testing of enterococci. Diagn Microbiol Infect Dis 2001;40:157-161.
5. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing, 16th informational supplement. Document M100-S16. CLSI Press, Wayne, PA, 2006.
6. National Committee for Clinical Laboratory Standards (NCCLS). Development of in vitro susceptibility testing criteria and quality control parameters; tentative guideline M23-T2. NCCLS Press, Villanova, PA,, 1992.
7. Sade HS, Fritsche TR, Jones RN. Accuracy of three automated systems (MicroScan WalkAway, VITEK, and VITEK2) for susceptibility testing of Pseudomonas aeruginosa against five broad-spectrum beta-lactam agents. J Clin Microbiol 2006;44:1101-1104.
8. Ballow CH, Jones RN, Biedenbach DJ. A multicenter evaluation of linezolid antimicrobial activity in North America. Diagn Microbiol Infect Dis 2002;43:75-83.
9. Smith DL, Johnson JA, Harris AD, Furuno JP, Perencevich EN, Morris JG Jr. Assessing risks for a pre-emergent pathogen: virginiamycin use and the emergence of streptogramin resistance in Enterococcus faecium. Lancet Infect Dis 2003;3:241-249.
10. Jevitt LA, Smith AJ, Williams PP, Raney PM, McGowan JE Jr, Tenover FC. In vitro activities of daptomycin, linezolid, and quinupristin-dalfopristin against a challenge panel of staphylococci and enterococci, including vancomycin-intermediate Staphylococcus aureus and vancomycin-resistant Enterococcus faecium. Microb Drug Resist 2003; 9:389-393.
11. Low DE, Keller N, Barth A, Jones RN. Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY antimicrobial surveillance program, 1997-1999. Clin Inf Dis 2001;32(Suppl.2):S133-S145.
12. Sader HS, Jones RN, Ballow CH, Biedenbach DJ, Cered RF, the GSMART Latin America Study Group. Antimicrobial susceptibility of quinupristin/dalfopristin tested against gram-positive cocci from Latin America: results from the global SMART (GSMART) surveillance study. Braz J Infect Dis 2001;5:21-31.
13. Simonsen GS, Bergh K, Bevanger L, Digranes A, Gaustad P, Melby KK, Hoiby EA. Susceptibility to quinupristin-dalfopristin and linezolid in 839 clinical isolates of Gram-positive cocci from Norway. Scand J Infect Dis 2004;35:254-258.
14. Torres-Vierak, C, Dembry LM. Approaches to vancomycin-resistant enterococci. Curr Opin Infect Dis 2004;17:541-547.